Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial

DOI PDF 2 Citations

Geert Leroux-Roels

Center for Vaccinology, Ghent University and University Hospital, Belgium
Jakob P Cramer

Takeda Pharmaceuticals International AG, Zurich, Switzerland
Paul M Mendelman

Takeda Vaccines Inc, Boston, Massachusetts
James Sherwood

Takeda Pharmaceuticals International AG, Zurich, Switzerland
Ralf Clemens

Takeda Pharmaceuticals International AG, Zurich, Switzerland
Annelies Aerssens

Center for Vaccinology, Ghent University and University Hospital, Belgium
Ilse De Coster

Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Belgium
Astrid Borkowski

Takeda Pharmaceuticals International AG, Zurich, Switzerland
Frank Baehner

Takeda Pharmaceuticals International AG, Zurich, Switzerland
Pierre Van Damme

Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Belgium

Journal

The Journal of Infectious Diseases

The Journal of Infectious Diseases 217 (4), 597-607, 2017-11-13

Oxford University Press (OUP)

Back to top